AsymBio
AsymBio is a biopharmaceutical CDMO and subsidiary of Asymchem Group providing end-to-end biologics development and manufacturing services (antibodies, recombinant proteins, ADCs, novel drug conjugates, mRNA) for global pharma and biotech clients across a Shanghai-based three-facility manufacturing network compliant with NMPA, FDA, and EMA standards.
- Company typePrivate
- Founded2019
- HeadquartersWoburn, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingServices
What AsymBio does
AsymBio (凯莱英生物技术有限公司) is a biopharmaceutical contract development and manufacturing organization (CDMO) and wholly-owned subsidiary of Asymchem Group (002821.SZ / 6821.HK), founded in January 2019. The company provides end-to-end CDMO services across the full biopharmaceutical development lifecycle for global pharmaceutical and biotech clients, spanning early-stage research, process development, toxicology and clinical batches, and commercial-scale manufacturing for biologics including monoclonal antibodies, bispecific antibodies, recombinant proteins, antibody-drug conjugates (ADCs), novel drug conjugates (RDCs, AOCs, PDCs, APCs, bispecific ADCs, dual-payload ADCs), and mRNA therapeutics.
The company's core technology consists of seven integrated platforms: the proprietary AmigoCHO Cell Line Development Platform achieving 8 g/L expression levels in 7 weeks; Upstream and Downstream Process Development Platforms with upstream timelines shortened to 9 weeks; the Conjugation Toolbox supporting multiple conjugation modalities (cysteine, lysine, engineered cysteine, interchain bridging, enzymatic via mTG/sortase, and glyco-remodeling via GlycoConnect, GlycoT, DisacLink, iGDC); the IMPACT Drug Product Development Platform; the Payload-Linker CMC Development Platform supporting 70+ IND and 13 NDA projects; and a Comprehensive Analytical Platform integrating physicochemical, mass spectrometry, and bioassay capabilities. Operations are conducted across a Shanghai "Golden Triangle" network: the Zhangjiang Center of Biological Technology and Innovation (CBTI), the Jinshan manufacturing site, and the 130,000+ square meter Fengxian Commercial Production Base (66,000L bioreactor capacity, 2 million vial annual capacity), with a US business development office in Woburn, MA. Facilities are compliant with NMPA, FDA, and EMA standards.
AsymBio operates a project-based B2B contract services revenue model with pricing specific to each engagement. Go-to-market is event-driven enterprise field sales, with active participation in major industry conferences (World ADC, BIOCHINA, Festival of Biologics, ADC Asia Congress) and direct engagement through a business development team. Customer concentration is horizontal across pharmaceutical and biotech companies globally, with the company leveraging the Asymchem Group ecosystem including Tianjin's payload-linker manufacturing capabilities for integrated supply chain advantages.
AsymBio firmographics
Firmographics- Name
- AsymBio
- Legal name
- 凯莱英生物技术有限公司
- Website
- https://asymbio.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- AsymBio is a biopharmaceutical CDMO and subsidiary of Asymchem Group providing end-to-end biologics development and manufacturing services (antibodies, recombinant proteins, ADCs, novel drug conjugates, mRNA) for global pharma and biotech clients across a Shanghai-based three-facility manufacturing network compliant with NMPA, FDA, and EMA standards.
- Ownership category
- akta.pro rank
AsymBio industry classification
Industry- Product category
- Biologics Contract Development and Manufacturing (CDMO) Services
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)
- akta.pro secondary industries
- Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE), mRNA/LNP & Nucleic Acid Therapeutics CDMO (HLAGABAF), Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH)
Keywords
Where AsymBio is headquartered
LocationHeadquarters
- HQ city
- Woburn
- HQ country
- United States
- HQ region
- North America
Offices5 records
Markets served
AsymBio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Revenue model
- Biopharmaceutical CDMO Services: Full-service contract development and manufacturing organization providing one-stop CDMO solutions for biologics including antibodies, recombinant proteins, and novel drug conjugates. Services span early-stage research, process development, toxicology batches, clinical batches, and commercial-scale manufacturing. Revenue generated through project-based contracts with pharmaceutical and biotech companies.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
AsymBio product offering
Product offeringCore offering
AsymBio provides one-stop biologics contract development and manufacturing organization (CDMO) services for global pharmaceutical and biotech companies, spanning the full biopharmaceutical lifecycle from cell line development, upstream and downstream process development, conjugation, drug product development, and analytical services through to clinical and commercial-scale manufacturing for antibodies, recombinant proteins, novel drug conjugates (ADCs, RDCs, AOCs, PDCs, BsADCs), and mRNA products.
Product overview
AsymBio is a technology-driven biologics CDMO and subsidiary of Asymchem Group providing integrated one-stop CDMO services spanning the full biopharmaceutical development lifecycle. The company operates seven integrated technology platforms: AmigoCHO Cell Line Development Platform for high-titer clone development; Upstream and Downstream Process Development Platforms for IND-enabling workflows; Conjugation Toolbox for ADC and bioconjugate process development supporting random and site-specific conjugation technologies; IMPACT Drug Product Development Platform for formulation solutions; Payload-Linker CMC Development Platform supporting 70+ IND and 13 NDA projects; and Comprehensive Analytical Platform for physicochemical, mass spectrometry, and bioassay characterization. The company provides end-to-end services from early-stage research through commercial-scale manufacturing across antibodies, ADCs, novel drug conjugates (RDCs, AOCs, PDCs, APCs, BsADCs, dpADCs), mRNA, and recombinant proteins, supported by three Shanghai facilities (Zhangjiang CBTI, Jinshan, and Fengxian) compliant with NMPA, FDA, and EMA standards.
Differentiator
Problem solved
Functional benefit
Products and services
- AmigoCHO Cell Line Development Platform Proprietary cell line development platform supporting high-titer, high-quality, and stable clone development including cell pool establishment, expansion, clone selection, and stability analysis for monoclonal antibodies, bispecific antibodies, ADCs, enzymes, and fusion proteins. Achieves 8 g/L expression levels and 7-week timelines.
- Conjugation Toolbox Modular technology platform for rapid development and optimization of diverse bioconjugate modalities (ADCs, RDCs, AOCs, APCs, bispecific ADCs, dual-payload ADCs) supporting both random and site-specific conjugation technologies including cysteine-, lysine-, engineered cysteine-, interchain cysteine re-bridging-, enzymatic (mTG, sortase)-, and glyco-remodeling-based (GlycoConnect, GlycoT, DisacLink, iGDC) approaches.
- IMPACT Drug Product Development Platform Indication-, Molecule-, and Phase-Accountable drug product development platform delivering formulation and process solutions for complex and high-potency biologics across liquid, lyophilized, high-concentration, and multi-dose presentations.
- Payload-Linker CMC Development Platform CMC development platform offering multiple payload options (Auristatin, Maytansine, Camptothecin, Eribulin, PBD dimer, macrocyclic molecular glue, E3 ligase ligand) and linker options (peptide, PEG, sugar linkers), supporting ADC and bioconjugate CMC development.
- Comprehensive Analytical Platform Integrated analytical platform comprising a Physicochemical Platform, Mass Spectrometry Platform, and Bioassay Platform for efficient analytical method development and in-depth product characterization covering critical quality attributes across the product lifecycle.
- Upstream Process Development Platform Process optimization, scale-up, and characterization platform supporting workflows from preclinical material preparation and IND/BLA-enabling process development through technology transfer and scale-up, with project timelines shortenable to as little as 9 weeks.
- Downstream Process Development Platform Downstream process development platform supporting chromatography process development, filtration process development, tech transfer and scale-up, and process characterization to shorten timelines while improving purity, reducing impurities, and increasing yield.
- Developability Assessment Service bridging late-stage discovery with early CMC development for candidate drug preparation and developability assessment, integrating cloning/expression/purification/conjugation processes for drug substance manufacturing.
- Antibodies & Recombinant Biotherapeutics CDMO Services End-to-end CDMO services covering cell line construction, upstream/downstream process development, drug substance and drug product manufacturing, and release testing for monoclonal antibodies, bispecific antibodies, and fusion proteins.
- Bioconjugates CDMO Services Comprehensive bioconjugate services including payload-linker CMC, antibody intermediate manufacturing, bioconjugate process development, drug substance/product manufacturing, and release testing for ADCs, RDCs, AOCs, PDCs, and other novel drug conjugates.
- mRNA CDMO Services Full mRNA CDMO services including plasmid linearization process development, in vitro mRNA transcription, mRNA-LNP process development, mRNA production, and mRNA release testing.
- Analytical Science & Quality Control Services Physicochemical analysis of recombinant biotherapeutics and bioconjugates, mass spectrometry analysis, bioassay development, release testing, and stability studies.
- Regulatory Affairs Services Comprehensive CMC dossier templates, regulatory guideline interpretation, and CMC knowledge sharing with experience in biologics IND, BLA, and NDA applications.
- Shanghai Fengxian Commercial Production Base 130,000+ square meter smart manufacturing facility offering 66,000L of drug substance capacity (Phase IA) and up to two million vials annually (Phase IB), compliant with NMPA, FDA, and EMA standards for antibodies, ADCs, NDCs, and recombinant proteins.
- Jinshan Manufacturing Site
- Zhangjiang Center of Biological Technology and Innovation (CBTI) Technology-driven central R&D center focusing on early R&D and process development for antibodies, proteins, novel drug conjugates, and advanced therapies, building and optimizing the technology platforms for cell line development, process development, conjugation toolbox, and analytical method development.
Quantifiable outcome
- IND-enabling conjugation process development can be completed in 2-3 months
- +5 more outcomes
Companies that use AsymBio
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
AsymBio technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
AsymBio partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- Radiopharm TheranosticscoreStrategic partnership for novel drug conjugate (NDC) CMC development. AsymBio served as strategic partner supporting CMC studies for IND submission of Betabart (RV-01), a Lu177-B7H3 radiopharmaceutical. FDA IND approval achieved in 2025.
- T-E MedscoreStrategic cooperation agreement signed to drive innovation in drug conjugates and explore the future of targeted therapeutics. Partnership marks beginning of deep collaboration in targeted therapeutics development.
- Synaffix (now Lonza)coreTechnology partnership for GlycoConnect glyco-remodeling conjugation technology. AsymBio has established CMC development expertise with GlycoConnect technology for site-specific ADC conjugation.
- Asymchem GroupcoreParent company and strategic business unit of Asymchem Group (stock codes: 002821.SZ / 6821.HK). AsymBio integrates with Group resources including Tianjin payload-linker R&D and manufacturing facilities.
Scale indicators12 records
Recent moves9 records
Expansion highlights5 records
AsymBio competitors and assessment
Company assessmentRegional players
- Celltrion: Korean biopharmaceutical company with biologics manufacturing capabilities for biosimilars and innovative biologics. Comparable as a regional player in Asia-Pacific biologics manufacturing with overlapping capabilities.
Direct peers
- Mabwell: Chinese biopharmaceutical company with growing biologics CDMO services supporting antibody and recombinant protein development and manufacturing. Comparable to AsymBio as a China-headquartered biologics CDMO.
- WuXi Biologics: Largest China-based biologics CDMO offering end-to-end antibody, recombinant protein, ADC, and bioconjugate development and manufacturing services globally. Directly comparable to AsymBio across biologics modalities, customer base (global pharma/biotech), and integrated one-stop CDMO model.
- AGC Biologics: Global contract development and manufacturing organization specializing in mammalian and microbial biologics, with capabilities spanning cell line development through commercial manufacturing. Comparable to AsymBio as a similarly scaled CDMO focused on biologics.
- Genscript Biotech: China-rooted life sciences company with biopharmaceutical CDMO services (Bestzyme, GenScript ProBio) offering biologics development and manufacturing. Comparable as a Chinese-based biologics CDMO serving global biotech clients.
Broad incumbents
- Catalent: Major global CDMO with biologics, ADC, and drug product capabilities across fill-finish and commercial manufacturing. Comparable as a broad incumbent offering biologics CDMO services to pharma and biotech clients.
- Lonza Group: Global leader in biologics CDMO with deep expertise in mammalian cell culture, ADCs (via acquired Synaffix platform, which AsymBio partners with), and commercial-scale manufacturing. Comparable as a global incumbent offering overlapping capabilities, though broader in scope than AsymBio's biologics focus.
- Samsung Biologics: Korean global biologics CDMO with very large-scale commercial manufacturing capacity and broad service offerings from cell line to commercial supply. Comparable as an established incumbent in biologics CDMO serving global pharma clients.
- Pharmaron: China-rooted global CRO/CDMO with growing biologics CDMO capabilities alongside established small-molecule services. Comparable as a parent-affiliated biopharmaceutical services platform with overlapping biologics offerings and Asymchem Group's broader competitive set.
- Boehringer Ingelheim BioXcellence: Global biologics CDMO division of Boehringer Ingelheim offering mammalian cell culture, microbial, and bioconjugate manufacturing. Comparable as an established global CDMO serving pharma clients with biologics outsourcing needs.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
AsymBio social profiles
Digital presenceAsymBio compliance and trust
Trust signalCompliance5 records
AsymBio financial estimates
Financial estimateRevenue estimate
Valuation estimate
AsymBio leadership team
Management profileNumber of profiles
Profiles12 records
AsymBio funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AsymBio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AsymBio
What does AsymBio do?
AsymBio provides one-stop biologics contract development and manufacturing organization (CDMO) services for global pharmaceutical and biotech companies, spanning the full biopharmaceutical lifecycle from cell line development, upstream and downstream process development, conjugation, drug product development, and analytical services through to clinical and commercial-scale manufacturing for antibodies, recombinant proteins, novel drug conjugates (ADCs, RDCs, AOCs, PDCs, BsADCs), and mRNA products.
Is AsymBio a public or private company?
AsymBio is a private company. It is classified as corporate owned and is currently operating.
When was AsymBio founded?
AsymBio was founded in 2019. It employs 501 to 1,000 people.
Where is AsymBio based?
AsymBio is headquartered in Woburn, United States, in the North America region.
How does AsymBio make money?
One revenue line is on record: biopharmaceutical CDMO Services.
Who are AsymBio's main competitors?
Celltrion is listed as a regional player. Direct peers are Mabwell, WuXi Biologics, AGC Biologics and Genscript Biotech. Broad incumbents are Catalent, Lonza Group, Samsung Biologics, Pharmaron and Boehringer Ingelheim BioXcellence.
Does AsymBio have an API?
No public API is recorded for AsymBio.
What industry is AsymBio in?
AsymBio's product category is Biologics Contract Development and Manufacturing (CDMO) Services. Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAGABAE, Gene Therapy (Viral Vector/Plasmid) CDMO. Its NAICS code is 325414 and its SIC code is 2834.